| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 67 | 2024 | 325 | 9.270 |
Why?
|
| Antirheumatic Agents | 44 | 2024 | 213 | 5.640 |
Why?
|
| Registries | 43 | 2024 | 804 | 2.830 |
Why?
|
| Biological Products | 13 | 2024 | 94 | 2.210 |
Why?
|
| Severity of Illness Index | 21 | 2024 | 1448 | 1.600 |
Why?
|
| Tumor Necrosis Factor-alpha | 19 | 2024 | 582 | 1.450 |
Why?
|
| Depression | 6 | 2016 | 859 | 1.260 |
Why?
|
| Middle Aged | 100 | 2025 | 16250 | 1.210 |
Why?
|
| Rheumatology | 8 | 2016 | 65 | 1.200 |
Why?
|
| Female | 140 | 2025 | 30886 | 1.180 |
Why?
|
| Male | 128 | 2025 | 27550 | 1.160 |
Why?
|
| Aged | 95 | 2025 | 13339 | 1.130 |
Why?
|
| Gonorrhea | 10 | 2022 | 196 | 1.120 |
Why?
|
| Humans | 163 | 2025 | 59426 | 0.930 |
Why?
|
| Cardiovascular Diseases | 10 | 2024 | 819 | 0.880 |
Why?
|
| Adult | 74 | 2025 | 15761 | 0.870 |
Why?
|
| Self Report | 4 | 2014 | 366 | 0.860 |
Why?
|
| Neisseria gonorrhoeae | 10 | 2022 | 258 | 0.820 |
Why?
|
| Treatment Outcome | 44 | 2024 | 5170 | 0.800 |
Why?
|
| Time Factors | 26 | 2021 | 3577 | 0.750 |
Why?
|
| Stress, Psychological | 6 | 2012 | 443 | 0.740 |
Why?
|
| Cohort Studies | 26 | 2021 | 2443 | 0.670 |
Why?
|
| Self Care | 3 | 2011 | 211 | 0.660 |
Why?
|
| Counseling | 8 | 2013 | 352 | 0.620 |
Why?
|
| Methotrexate | 7 | 2021 | 76 | 0.600 |
Why?
|
| Markov Chains | 1 | 2017 | 37 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2018 | 740 | 0.550 |
Why?
|
| Arthritis, Psoriatic | 4 | 2024 | 31 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2011 | 670 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 60 | 0.520 |
Why?
|
| Prevalence | 10 | 2024 | 1284 | 0.480 |
Why?
|
| Rituximab | 4 | 2016 | 82 | 0.480 |
Why?
|
| Proportional Hazards Models | 13 | 2021 | 673 | 0.470 |
Why?
|
| Patient Readmission | 3 | 2014 | 420 | 0.460 |
Why?
|
| Incidence | 14 | 2024 | 1237 | 0.460 |
Why?
|
| Patients | 2 | 2013 | 103 | 0.450 |
Why?
|
| Remission Induction | 8 | 2020 | 137 | 0.450 |
Why?
|
| Antibodies, Bacterial | 5 | 2021 | 193 | 0.450 |
Why?
|
| Conduct Disorder | 1 | 2013 | 23 | 0.440 |
Why?
|
| United States | 36 | 2024 | 7513 | 0.430 |
Why?
|
| Diabetes Complications | 2 | 2014 | 102 | 0.430 |
Why?
|
| Risk Factors | 21 | 2024 | 5010 | 0.430 |
Why?
|
| Pain Measurement | 3 | 2024 | 330 | 0.420 |
Why?
|
| Receptors, IgG | 1 | 2012 | 36 | 0.410 |
Why?
|
| Poverty | 3 | 2011 | 286 | 0.410 |
Why?
|
| Drug Substitution | 5 | 2016 | 41 | 0.410 |
Why?
|
| Health Behavior | 6 | 2011 | 470 | 0.410 |
Why?
|
| Obesity | 9 | 2022 | 1185 | 0.400 |
Why?
|
| Perception | 1 | 2013 | 179 | 0.400 |
Why?
|
| Child Abuse, Sexual | 1 | 2012 | 21 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 856 | 0.400 |
Why?
|
| Surveys and Questionnaires | 17 | 2020 | 2594 | 0.400 |
Why?
|
| Immunoglobulin G | 8 | 2023 | 452 | 0.400 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2012 | 13 | 0.400 |
Why?
|
| Primary Prevention | 1 | 2013 | 137 | 0.400 |
Why?
|
| Joints | 3 | 2012 | 30 | 0.400 |
Why?
|
| Professional-Patient Relations | 2 | 2012 | 128 | 0.400 |
Why?
|
| Multivariate Analysis | 9 | 2019 | 925 | 0.400 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 194 | 0.390 |
Why?
|
| North America | 10 | 2022 | 114 | 0.390 |
Why?
|
| Multilingualism | 1 | 2012 | 22 | 0.390 |
Why?
|
| Communication Barriers | 1 | 2012 | 59 | 0.390 |
Why?
|
| Physicians, Family | 1 | 2012 | 75 | 0.380 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2013 | 107 | 0.380 |
Why?
|
| Venous Thromboembolism | 5 | 2012 | 140 | 0.380 |
Why?
|
| Adolescent | 17 | 2013 | 5917 | 0.380 |
Why?
|
| Length of Stay | 3 | 2014 | 768 | 0.370 |
Why?
|
| Prospective Studies | 15 | 2024 | 3096 | 0.370 |
Why?
|
| Smoking | 3 | 2013 | 829 | 0.370 |
Why?
|
| Residence Characteristics | 2 | 2012 | 224 | 0.370 |
Why?
|
| Massachusetts | 18 | 2014 | 2095 | 0.370 |
Why?
|
| Hydroxychloroquine | 2 | 2021 | 18 | 0.370 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 299 | 0.370 |
Why?
|
| Peripheral Arterial Disease | 5 | 2021 | 156 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2016 | 715 | 0.360 |
Why?
|
| Aged, 80 and over | 27 | 2014 | 5098 | 0.360 |
Why?
|
| Bacterial Vaccines | 3 | 2021 | 90 | 0.360 |
Why?
|
| Cholesterol, LDL | 7 | 2024 | 105 | 0.360 |
Why?
|
| Health Literacy | 1 | 2011 | 77 | 0.340 |
Why?
|
| Inflammation | 7 | 2024 | 1096 | 0.340 |
Why?
|
| Curriculum | 2 | 2013 | 554 | 0.340 |
Why?
|
| Primary Health Care | 5 | 2014 | 649 | 0.330 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 237 | 0.330 |
Why?
|
| Predictive Value of Tests | 8 | 2014 | 1027 | 0.330 |
Why?
|
| Neoplasms | 5 | 2015 | 1244 | 0.320 |
Why?
|
| Metabolic Syndrome | 2 | 2024 | 148 | 0.320 |
Why?
|
| Longitudinal Studies | 10 | 2015 | 1225 | 0.310 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 560 | 0.310 |
Why?
|
| Health Maintenance Organizations | 4 | 2006 | 87 | 0.310 |
Why?
|
| Epitopes | 3 | 2021 | 295 | 0.310 |
Why?
|
| Health Personnel | 1 | 2012 | 342 | 0.310 |
Why?
|
| Health Promotion | 5 | 2011 | 491 | 0.300 |
Why?
|
| Pain | 2 | 2014 | 405 | 0.290 |
Why?
|
| Follow-Up Studies | 15 | 2017 | 2327 | 0.290 |
Why?
|
| Public Health | 2 | 2009 | 180 | 0.290 |
Why?
|
| Health Status Indicators | 1 | 2008 | 98 | 0.290 |
Why?
|
| Homes for the Aged | 4 | 2014 | 164 | 0.290 |
Why?
|
| Research Design | 5 | 2015 | 567 | 0.290 |
Why?
|
| Anticoagulants | 6 | 2012 | 485 | 0.280 |
Why?
|
| Lipopolysaccharides | 3 | 2019 | 645 | 0.280 |
Why?
|
| Sex Factors | 12 | 2017 | 961 | 0.280 |
Why?
|
| Child, Preschool | 7 | 2018 | 1838 | 0.280 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2018 | 48 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2016 | 672 | 0.270 |
Why?
|
| Body Mass Index | 7 | 2019 | 885 | 0.270 |
Why?
|
| School Nursing | 3 | 2013 | 26 | 0.270 |
Why?
|
| Plasmodium chabaudi | 2 | 2018 | 23 | 0.260 |
Why?
|
| Drug Monitoring | 4 | 2014 | 96 | 0.250 |
Why?
|
| Hostility | 1 | 2005 | 17 | 0.250 |
Why?
|
| C-Reactive Protein | 4 | 2024 | 167 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 501 | 0.250 |
Why?
|
| Warfarin | 3 | 2012 | 109 | 0.250 |
Why?
|
| Personality | 1 | 2005 | 25 | 0.250 |
Why?
|
| Smoking Cessation | 4 | 2013 | 531 | 0.250 |
Why?
|
| Attitude to Health | 6 | 2011 | 275 | 0.250 |
Why?
|
| Enteritis | 1 | 2025 | 13 | 0.240 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 61 | 0.240 |
Why?
|
| Ulcer | 1 | 2025 | 15 | 0.240 |
Why?
|
| Age Factors | 11 | 2017 | 1516 | 0.240 |
Why?
|
| Hypercholesterolemia | 3 | 2011 | 68 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2018 | 231 | 0.240 |
Why?
|
| Testosterone | 1 | 2005 | 111 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2021 | 200 | 0.240 |
Why?
|
| Adipokines | 1 | 2024 | 28 | 0.240 |
Why?
|
| Hydrocortisone | 2 | 2004 | 188 | 0.240 |
Why?
|
| Prednisone | 3 | 2021 | 80 | 0.240 |
Why?
|
| Immunization, Passive | 3 | 2021 | 100 | 0.240 |
Why?
|
| Intestinal Obstruction | 1 | 2025 | 50 | 0.240 |
Why?
|
| Fibromyalgia | 1 | 2024 | 15 | 0.230 |
Why?
|
| Comorbidity | 8 | 2015 | 1090 | 0.230 |
Why?
|
| Intestine, Small | 1 | 2025 | 75 | 0.230 |
Why?
|
| Lymphoma | 2 | 2015 | 99 | 0.230 |
Why?
|
| Cross-Sectional Studies | 11 | 2023 | 2473 | 0.230 |
Why?
|
| Social Support | 2 | 2004 | 360 | 0.230 |
Why?
|
| Risk Assessment | 11 | 2017 | 1912 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2014 | 212 | 0.230 |
Why?
|
| Lung Diseases | 1 | 2005 | 164 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2024 | 220 | 0.220 |
Why?
|
| Infliximab | 4 | 2019 | 55 | 0.220 |
Why?
|
| Bacterial Infections | 2 | 2016 | 138 | 0.220 |
Why?
|
| Child | 11 | 2018 | 4305 | 0.220 |
Why?
|
| Quality of Life | 7 | 2017 | 1118 | 0.220 |
Why?
|
| Altruism | 1 | 2003 | 13 | 0.220 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 303 | 0.220 |
Why?
|
| Retrospective Studies | 13 | 2025 | 6001 | 0.220 |
Why?
|
| Crohn Disease | 1 | 2025 | 113 | 0.220 |
Why?
|
| Death | 1 | 2003 | 24 | 0.220 |
Why?
|
| Tobacco Use Disorder | 3 | 2013 | 245 | 0.220 |
Why?
|
| Prescription Drugs | 2 | 2014 | 50 | 0.210 |
Why?
|
| Disability Evaluation | 2 | 2015 | 216 | 0.210 |
Why?
|
| Continuity of Patient Care | 2 | 2014 | 172 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 7 | 2021 | 879 | 0.200 |
Why?
|
| Peptides | 3 | 2019 | 545 | 0.200 |
Why?
|
| Propensity Score | 4 | 2016 | 134 | 0.200 |
Why?
|
| Glucocorticoids | 2 | 2021 | 172 | 0.200 |
Why?
|
| Venous Thrombosis | 3 | 2021 | 106 | 0.200 |
Why?
|
| Nursing Homes | 4 | 2014 | 665 | 0.200 |
Why?
|
| Coinfection | 1 | 2022 | 45 | 0.200 |
Why?
|
| Patient Satisfaction | 5 | 2011 | 411 | 0.200 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 77 | 0.200 |
Why?
|
| Sulfasalazine | 1 | 2021 | 5 | 0.190 |
Why?
|
| Young Adult | 5 | 2012 | 4319 | 0.190 |
Why?
|
| Odds Ratio | 9 | 2015 | 773 | 0.190 |
Why?
|
| Capsule Endoscopy | 1 | 2021 | 38 | 0.180 |
Why?
|
| Myocardial Infarction | 5 | 2021 | 860 | 0.180 |
Why?
|
| Meditation | 3 | 2012 | 60 | 0.180 |
Why?
|
| Community Health Services | 3 | 2011 | 128 | 0.180 |
Why?
|
| Patient Compliance | 3 | 2012 | 371 | 0.180 |
Why?
|
| Confidence Intervals | 5 | 2014 | 255 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 324 | 0.180 |
Why?
|
| Pulmonary Embolism | 3 | 2021 | 170 | 0.180 |
Why?
|
| Truth Disclosure | 3 | 2006 | 54 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 537 | 0.180 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 495 | 0.180 |
Why?
|
| Immunologic Factors | 2 | 2012 | 99 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 86 | 0.180 |
Why?
|
| Dementia | 2 | 2014 | 247 | 0.170 |
Why?
|
| Mental Health | 1 | 2003 | 350 | 0.170 |
Why?
|
| Mycoplasma genitalium | 1 | 2020 | 3 | 0.170 |
Why?
|
| Urethritis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Mycoplasma Infections | 1 | 2020 | 6 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 80 | 0.170 |
Why?
|
| Mice | 15 | 2021 | 10272 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 118 | 0.170 |
Why?
|
| Infant | 5 | 2018 | 1522 | 0.160 |
Why?
|
| Abatacept | 2 | 2016 | 63 | 0.160 |
Why?
|
| Pilot Projects | 5 | 2016 | 922 | 0.160 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2018 | 61 | 0.160 |
Why?
|
| Medical Errors | 3 | 2006 | 193 | 0.160 |
Why?
|
| Terminal Care | 3 | 2005 | 95 | 0.160 |
Why?
|
| Ambulatory Care | 3 | 2014 | 300 | 0.160 |
Why?
|
| Bone Density | 2 | 2010 | 174 | 0.160 |
Why?
|
| Health Status | 4 | 2012 | 449 | 0.160 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 432 | 0.150 |
Why?
|
| Lactose | 1 | 2018 | 13 | 0.150 |
Why?
|
| Heptoses | 1 | 2018 | 12 | 0.150 |
Why?
|
| Complement Factor H | 2 | 2018 | 146 | 0.150 |
Why?
|
| Infant, Newborn | 5 | 2012 | 1306 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2021 | 309 | 0.150 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2018 | 49 | 0.150 |
Why?
|
| Rheumatologists | 1 | 2018 | 7 | 0.150 |
Why?
|
| Plasmodium | 1 | 2018 | 29 | 0.150 |
Why?
|
| Quality of Health Care | 4 | 2012 | 519 | 0.150 |
Why?
|
| Smoking Prevention | 2 | 2011 | 162 | 0.150 |
Why?
|
| Psychometrics | 3 | 2012 | 356 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2011 | 265 | 0.150 |
Why?
|
| Socioeconomic Factors | 4 | 2011 | 782 | 0.150 |
Why?
|
| Physician-Patient Relations | 3 | 2006 | 392 | 0.140 |
Why?
|
| Inservice Training | 1 | 2018 | 84 | 0.140 |
Why?
|
| Office Visits | 2 | 2014 | 41 | 0.140 |
Why?
|
| Disease Progression | 4 | 2017 | 1045 | 0.140 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 98 | 0.140 |
Why?
|
| Regression Analysis | 5 | 2015 | 483 | 0.140 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 303 | 0.140 |
Why?
|
| Malaria | 1 | 2018 | 101 | 0.140 |
Why?
|
| Patient Education as Topic | 5 | 2012 | 446 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2010 | 254 | 0.140 |
Why?
|
| Biological Factors | 1 | 2016 | 23 | 0.140 |
Why?
|
| Guideline Adherence | 3 | 2016 | 296 | 0.140 |
Why?
|
| Malaria, Falciparum | 1 | 2018 | 115 | 0.130 |
Why?
|
| Animals | 16 | 2021 | 19643 | 0.130 |
Why?
|
| Acute Disease | 4 | 2021 | 658 | 0.130 |
Why?
|
| Pharmacogenetics | 2 | 2014 | 21 | 0.130 |
Why?
|
| Biomarkers | 4 | 2015 | 1197 | 0.130 |
Why?
|
| Myocardial Revascularization | 2 | 2021 | 71 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 115 | 0.130 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 9 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2025 | 736 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 2 | 2006 | 74 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 2 | 2007 | 56 | 0.130 |
Why?
|
| Hospitalization | 6 | 2021 | 1283 | 0.130 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 44 | 0.130 |
Why?
|
| Herpes Zoster | 1 | 2015 | 24 | 0.130 |
Why?
|
| Cytidine Monophosphate | 1 | 2015 | 15 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2015 | 38 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 2015 | 34 | 0.130 |
Why?
|
| Circadian Rhythm | 2 | 2018 | 369 | 0.130 |
Why?
|
| Spirituality | 2 | 2008 | 47 | 0.120 |
Why?
|
| Sialic Acids | 1 | 2015 | 46 | 0.120 |
Why?
|
| Risk | 2 | 2013 | 373 | 0.120 |
Why?
|
| Walking | 3 | 2007 | 229 | 0.120 |
Why?
|
| Medicare | 2 | 2010 | 600 | 0.120 |
Why?
|
| Data Collection | 3 | 2012 | 384 | 0.120 |
Why?
|
| Hemorrhage | 4 | 2010 | 268 | 0.120 |
Why?
|
| Leg | 2 | 2012 | 83 | 0.120 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 12 | 0.120 |
Why?
|
| Medical Futility | 1 | 2014 | 7 | 0.120 |
Why?
|
| Anticholesteremic Agents | 2 | 2012 | 34 | 0.120 |
Why?
|
| Reference Values | 5 | 2011 | 319 | 0.120 |
Why?
|
| Motor Activity | 3 | 2007 | 343 | 0.120 |
Why?
|
| Linear Models | 2 | 2012 | 422 | 0.120 |
Why?
|
| Alcohol-Related Disorders | 1 | 2014 | 36 | 0.120 |
Why?
|
| Adaptation, Psychological | 3 | 2008 | 264 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1539 | 0.120 |
Why?
|
| Drug Design | 1 | 2015 | 143 | 0.120 |
Why?
|
| Acute-Phase Proteins | 2 | 2014 | 34 | 0.120 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 8 | 0.110 |
Why?
|
| Genotype | 2 | 2012 | 636 | 0.110 |
Why?
|
| Recurrence | 6 | 2015 | 577 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2014 | 479 | 0.110 |
Why?
|
| Terminally Ill | 2 | 2005 | 17 | 0.110 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2015 | 138 | 0.110 |
Why?
|
| Fetal Diseases | 2 | 2004 | 21 | 0.110 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 24 | 0.110 |
Why?
|
| Child Day Care Centers | 1 | 2013 | 10 | 0.110 |
Why?
|
| Plasmodium vivax | 1 | 2014 | 31 | 0.110 |
Why?
|
| Malaria, Vivax | 1 | 2014 | 33 | 0.110 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2004 | 43 | 0.110 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2013 | 43 | 0.110 |
Why?
|
| Caspase 1 | 1 | 2014 | 110 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2013 | 84 | 0.110 |
Why?
|
| Antigens, Bacterial | 3 | 2021 | 214 | 0.110 |
Why?
|
| Prognosis | 2 | 2015 | 1572 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2016 | 330 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 2 | 2021 | 252 | 0.110 |
Why?
|
| Interviews as Topic | 4 | 2011 | 490 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2016 | 293 | 0.110 |
Why?
|
| Directive Counseling | 2 | 2011 | 39 | 0.110 |
Why?
|
| Pancreatic Function Tests | 1 | 2012 | 1 | 0.110 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2011 | 58 | 0.110 |
Why?
|
| Mothers | 1 | 2016 | 261 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 453 | 0.100 |
Why?
|
| Occult Blood | 2 | 2010 | 15 | 0.100 |
Why?
|
| Overweight | 2 | 2013 | 249 | 0.100 |
Why?
|
| Environment | 1 | 2013 | 125 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 46 | 0.100 |
Why?
|
| Population Surveillance | 3 | 2009 | 205 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2012 | 51 | 0.100 |
Why?
|
| Behavioral Medicine | 1 | 2012 | 40 | 0.100 |
Why?
|
| Plague | 1 | 2012 | 23 | 0.100 |
Why?
|
| Receptors, Interleukin-1 | 3 | 2007 | 64 | 0.100 |
Why?
|
| Yersinia pestis | 1 | 2012 | 33 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2013 | 77 | 0.100 |
Why?
|
| Domestic Violence | 1 | 2012 | 35 | 0.100 |
Why?
|
| Colonoscopy | 2 | 2010 | 103 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2013 | 149 | 0.100 |
Why?
|
| Inflammasomes | 2 | 2014 | 331 | 0.100 |
Why?
|
| Energy Intake | 2 | 2003 | 213 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2018 | 762 | 0.100 |
Why?
|
| Life Style | 4 | 2011 | 328 | 0.100 |
Why?
|
| Cystic Fibrosis | 1 | 2012 | 108 | 0.100 |
Why?
|
| Japan | 3 | 2016 | 57 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1055 | 0.100 |
Why?
|
| Seasons | 2 | 2004 | 130 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2012 | 147 | 0.100 |
Why?
|
| Cultural Competency | 1 | 2011 | 50 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 148 | 0.100 |
Why?
|
| Hypertension | 3 | 2021 | 600 | 0.100 |
Why?
|
| Burnout, Professional | 1 | 2013 | 123 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 401 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 796 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 448 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 37 | 0.090 |
Why?
|
| Intermittent Claudication | 1 | 2011 | 49 | 0.090 |
Why?
|
| Medication Adherence | 4 | 2018 | 254 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 311 | 0.090 |
Why?
|
| Attention | 1 | 2012 | 151 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 1548 | 0.090 |
Why?
|
| Telephone | 4 | 2012 | 121 | 0.090 |
Why?
|
| Opportunistic Infections | 1 | 2011 | 27 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2011 | 85 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2014 | 352 | 0.090 |
Why?
|
| Epidemiologic Methods | 4 | 2011 | 68 | 0.090 |
Why?
|
| Family Practice | 1 | 2012 | 205 | 0.090 |
Why?
|
| Eating | 2 | 2018 | 139 | 0.090 |
Why?
|
| Students, Medical | 1 | 2013 | 243 | 0.090 |
Why?
|
| Clinical Clerkship | 2 | 2013 | 84 | 0.090 |
Why?
|
| Hypotension | 1 | 2010 | 47 | 0.090 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 30 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2011 | 134 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2010 | 41 | 0.080 |
Why?
|
| Europe | 3 | 2016 | 183 | 0.080 |
Why?
|
| Community Networks | 2 | 2011 | 29 | 0.080 |
Why?
|
| Insurance Coverage | 1 | 2010 | 98 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 100 | 0.080 |
Why?
|
| Heart Failure | 2 | 2021 | 867 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 2067 | 0.080 |
Why?
|
| Urban Health | 1 | 2009 | 43 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2011 | 846 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 404 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2014 | 709 | 0.080 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 541 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 48 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 151 | 0.080 |
Why?
|
| Managed Care Programs | 2 | 2011 | 94 | 0.080 |
Why?
|
| Phenotype | 1 | 2012 | 1150 | 0.080 |
Why?
|
| Urban Population | 1 | 2009 | 182 | 0.080 |
Why?
|
| Psychotherapy | 1 | 2009 | 89 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 312 | 0.080 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 189 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 704 | 0.080 |
Why?
|
| Mammography | 1 | 2011 | 272 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 551 | 0.080 |
Why?
|
| Health Services for the Aged | 1 | 2008 | 48 | 0.080 |
Why?
|
| Medical Order Entry Systems | 1 | 2008 | 45 | 0.080 |
Why?
|
| Somatoform Disorders | 1 | 2008 | 13 | 0.080 |
Why?
|
| Aspirin | 2 | 2010 | 170 | 0.080 |
Why?
|
| Religion and Psychology | 1 | 2008 | 15 | 0.070 |
Why?
|
| Energy Metabolism | 2 | 2018 | 349 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2009 | 138 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 139 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 161 | 0.070 |
Why?
|
| Nutritional Status | 1 | 2009 | 118 | 0.070 |
Why?
|
| Asthma | 1 | 2012 | 419 | 0.070 |
Why?
|
| Lipids | 2 | 2024 | 307 | 0.070 |
Why?
|
| Antilymphocyte Serum | 1 | 2007 | 21 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2008 | 174 | 0.070 |
Why?
|
| Inpatients | 1 | 2010 | 295 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 749 | 0.070 |
Why?
|
| Cholesterol | 3 | 2004 | 255 | 0.070 |
Why?
|
| Demography | 2 | 2007 | 178 | 0.070 |
Why?
|
| Motivation | 1 | 2010 | 266 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2007 | 70 | 0.070 |
Why?
|
| Mice, Knockout | 5 | 2014 | 1988 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2009 | 307 | 0.070 |
Why?
|
| Triglycerides | 2 | 2005 | 242 | 0.070 |
Why?
|
| Health Surveys | 4 | 2010 | 306 | 0.070 |
Why?
|
| Program Evaluation | 4 | 2013 | 485 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2007 | 62 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 180 | 0.070 |
Why?
|
| Mucins | 1 | 2006 | 23 | 0.070 |
Why?
|
| Drug Utilization | 3 | 2014 | 223 | 0.070 |
Why?
|
| Advance Directives | 2 | 2004 | 46 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2018 | 527 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 48 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 36 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 331 | 0.070 |
Why?
|
| India | 2 | 2018 | 157 | 0.070 |
Why?
|
| Antibodies | 1 | 2007 | 176 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2009 | 249 | 0.070 |
Why?
|
| Outpatients | 1 | 2007 | 132 | 0.070 |
Why?
|
| International Normalized Ratio | 3 | 2012 | 34 | 0.070 |
Why?
|
| New England | 3 | 2014 | 268 | 0.070 |
Why?
|
| Uric Acid | 1 | 2006 | 49 | 0.070 |
Why?
|
| Pituitary-Adrenal System | 2 | 2004 | 60 | 0.070 |
Why?
|
| Etanercept | 3 | 2012 | 31 | 0.070 |
Why?
|
| Professional Competence | 1 | 2007 | 89 | 0.070 |
Why?
|
| Gout | 1 | 2006 | 53 | 0.060 |
Why?
|
| Communication | 1 | 2011 | 555 | 0.060 |
Why?
|
| Adalimumab | 3 | 2012 | 36 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2006 | 109 | 0.060 |
Why?
|
| Sweden | 2 | 2016 | 42 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2004 | 88 | 0.060 |
Why?
|
| Nalbuphine | 1 | 2005 | 3 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 193 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2012 | 576 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 286 | 0.060 |
Why?
|
| Attitude to Death | 1 | 2005 | 17 | 0.060 |
Why?
|
| Morphine | 1 | 2005 | 52 | 0.060 |
Why?
|
| Viremia | 1 | 2005 | 44 | 0.060 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 150 | 0.060 |
Why?
|
| Aggression | 1 | 2005 | 57 | 0.060 |
Why?
|
| Tobacco Use Cessation | 1 | 2005 | 30 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2025 | 21 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 319 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 42 | 0.060 |
Why?
|
| Dengue | 1 | 2005 | 93 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2007 | 266 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2025 | 102 | 0.060 |
Why?
|
| Adiponectin | 1 | 2024 | 33 | 0.060 |
Why?
|
| Dengue Virus | 1 | 2005 | 95 | 0.060 |
Why?
|
| Terrorism | 1 | 2004 | 16 | 0.060 |
Why?
|
| Leptin | 1 | 2024 | 78 | 0.060 |
Why?
|
| Emotions | 2 | 2004 | 217 | 0.060 |
Why?
|
| Life Change Events | 1 | 2004 | 66 | 0.060 |
Why?
|
| Spinal Dysraphism | 1 | 2004 | 16 | 0.060 |
Why?
|
| Encephalitis, Viral | 1 | 2004 | 5 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 142 | 0.060 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2024 | 6 | 0.060 |
Why?
|
| Washington | 1 | 2004 | 25 | 0.060 |
Why?
|
| Periodicity | 1 | 2004 | 50 | 0.060 |
Why?
|
| Oregon | 1 | 2004 | 19 | 0.060 |
Why?
|
| Life Support Care | 1 | 2004 | 20 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2016 | 638 | 0.060 |
Why?
|
| Mass Screening | 1 | 2009 | 647 | 0.060 |
Why?
|
| Patient Selection | 3 | 2014 | 447 | 0.060 |
Why?
|
| SEER Program | 1 | 2004 | 65 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2012 | 2886 | 0.060 |
Why?
|
| Christianity | 1 | 2003 | 4 | 0.060 |
Why?
|
| Nurse Practitioners | 1 | 2005 | 115 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 2004 | 43 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2005 | 149 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 66 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2004 | 99 | 0.050 |
Why?
|
| South America | 2 | 2015 | 22 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 416 | 0.050 |
Why?
|
| California | 1 | 2004 | 161 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2004 | 46 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2018 | 541 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2005 | 185 | 0.050 |
Why?
|
| Parents | 1 | 2007 | 381 | 0.050 |
Why?
|
| Meningomyelocele | 1 | 2003 | 11 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 73 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2011 | 798 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2003 | 77 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 192 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2003 | 92 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 48 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2003 | 39 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 723 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2004 | 118 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 57 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2002 | 17 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 94 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 903 | 0.050 |
Why?
|
| Bronchiolitis | 1 | 2002 | 17 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2002 | 84 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2024 | 205 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2007 | 1133 | 0.050 |
Why?
|
| Connecticut | 2 | 2012 | 86 | 0.050 |
Why?
|
| Thinness | 1 | 2022 | 41 | 0.050 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2002 | 33 | 0.050 |
Why?
|
| Advance Care Planning | 1 | 2002 | 61 | 0.050 |
Why?
|
| Angina, Unstable | 1 | 2021 | 57 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 439 | 0.050 |
Why?
|
| Defibrillators, Implantable | 1 | 2004 | 258 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 387 | 0.050 |
Why?
|
| Logistic Models | 3 | 2011 | 1252 | 0.050 |
Why?
|
| Women's Health | 2 | 2016 | 390 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 421 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2021 | 70 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2003 | 204 | 0.050 |
Why?
|
| Macrophages | 1 | 2006 | 1004 | 0.050 |
Why?
|
| Complement Activation | 1 | 2021 | 53 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 667 | 0.040 |
Why?
|
| Health Status Disparities | 2 | 2013 | 147 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 2 | 2014 | 246 | 0.040 |
Why?
|
| Critical Illness | 1 | 2004 | 332 | 0.040 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2020 | 8 | 0.040 |
Why?
|
| Self Efficacy | 2 | 2012 | 201 | 0.040 |
Why?
|
| Cell Line | 3 | 2013 | 2012 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1094 | 0.040 |
Why?
|
| Macrolides | 1 | 2020 | 38 | 0.040 |
Why?
|
| Stroke | 2 | 2021 | 1138 | 0.040 |
Why?
|
| Physicians | 1 | 2005 | 437 | 0.040 |
Why?
|
| Saliva | 1 | 2000 | 96 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 82 | 0.040 |
Why?
|
| Liver | 2 | 2018 | 784 | 0.040 |
Why?
|
| Adolescent Behavior | 2 | 2011 | 188 | 0.040 |
Why?
|
| Medication Errors | 2 | 2012 | 116 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 525 | 0.040 |
Why?
|
| Health Services Research | 2 | 2014 | 270 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2013 | 279 | 0.040 |
Why?
|
| Trophozoites | 1 | 2018 | 6 | 0.040 |
Why?
|
| Exercise | 4 | 2011 | 917 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 260 | 0.040 |
Why?
|
| Europe, Eastern | 1 | 2018 | 1 | 0.040 |
Why?
|
| Argentina | 1 | 2018 | 6 | 0.040 |
Why?
|
| Microbial Viability | 1 | 2018 | 56 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 42 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 71 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2018 | 48 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 38 | 0.040 |
Why?
|
| Brazil | 1 | 2018 | 86 | 0.040 |
Why?
|
| Host-Parasite Interactions | 1 | 2018 | 54 | 0.040 |
Why?
|
| China | 1 | 2018 | 141 | 0.040 |
Why?
|
| Leukocytes | 1 | 2018 | 99 | 0.040 |
Why?
|
| Program Development | 2 | 2011 | 210 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2008 | 188 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2018 | 68 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 195 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 141 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 279 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 3192 | 0.030 |
Why?
|
| Colorado | 2 | 2007 | 19 | 0.030 |
Why?
|
| Weight Loss | 2 | 2011 | 260 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 379 | 0.030 |
Why?
|
| ROC Curve | 2 | 2009 | 258 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2007 | 207 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 16 | 0.030 |
Why?
|
| Rheumatoid Factor | 1 | 2015 | 13 | 0.030 |
Why?
|
| Cytidine Monophosphate N-Acetylneuraminic Acid | 1 | 2015 | 12 | 0.030 |
Why?
|
| Virus Activation | 1 | 2015 | 24 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 69 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 13 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 23 | 0.030 |
Why?
|
| Radiography | 2 | 2010 | 508 | 0.030 |
Why?
|
| Bias | 1 | 2016 | 106 | 0.030 |
Why?
|
| Disease Management | 2 | 2009 | 220 | 0.030 |
Why?
|
| Diet | 2 | 2011 | 634 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 45 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 254 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 85 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 261 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 444 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2015 | 29 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 94 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 18 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2015 | 121 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 98 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 2015 | 126 | 0.030 |
Why?
|
| Psychotherapy, Brief | 1 | 2014 | 16 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 351 | 0.030 |
Why?
|
| Histones | 1 | 2018 | 463 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 593 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 24 | 0.030 |
Why?
|
| Insulin | 1 | 2018 | 686 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 724 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 250 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 72 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 2037 | 0.030 |
Why?
|
| Hospice Care | 1 | 2014 | 61 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 161 | 0.030 |
Why?
|
| Feeding Behavior | 2 | 2008 | 313 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 2013 | 57 | 0.030 |
Why?
|
| Toll-Like Receptors | 2 | 2006 | 434 | 0.030 |
Why?
|
| Preceptorship | 1 | 2013 | 41 | 0.030 |
Why?
|
| Control Groups | 1 | 2012 | 11 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2012 | 7 | 0.030 |
Why?
|
| Anticipation, Psychological | 1 | 2012 | 9 | 0.030 |
Why?
|
| Pancreatic Elastase | 1 | 2012 | 31 | 0.030 |
Why?
|
| Weight Gain | 2 | 2005 | 161 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2012 | 30 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2012 | 51 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2014 | 90 | 0.030 |
Why?
|
| Homozygote | 1 | 2012 | 116 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 172 | 0.030 |
Why?
|
| Feces | 1 | 2012 | 97 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 264 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 178 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2012 | 74 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 102 | 0.020 |
Why?
|
| Neonatal Screening | 1 | 2012 | 96 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 243 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2014 | 256 | 0.020 |
Why?
|
| Monocytes | 1 | 2014 | 345 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 138 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 165 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2012 | 204 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 208 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 45 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 410 | 0.020 |
Why?
|
| Financing, Government | 1 | 2011 | 33 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 158 | 0.020 |
Why?
|
| New Zealand | 1 | 2010 | 34 | 0.020 |
Why?
|
| Nursing Staff | 1 | 2011 | 41 | 0.020 |
Why?
|
| Nurse's Role | 1 | 2011 | 121 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2010 | 16 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 26 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 29 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2010 | 36 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 94 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 37 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 299 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 790 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 142 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 149 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 161 | 0.020 |
Why?
|
| Hip Joint | 1 | 2009 | 34 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 553 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2099 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 213 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2009 | 160 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2010 | 274 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2012 | 617 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2010 | 147 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2011 | 404 | 0.020 |
Why?
|
| Sick Role | 1 | 2008 | 15 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2008 | 50 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 679 | 0.020 |
Why?
|
| Reproduction | 1 | 2008 | 88 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 66 | 0.020 |
Why?
|
| Patient Participation | 1 | 2010 | 211 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 143 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 246 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 159 | 0.020 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2007 | 25 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2007 | 39 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 448 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2007 | 57 | 0.020 |
Why?
|
| Trefoil Factor-2 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Peroxidase | 1 | 2007 | 69 | 0.020 |
Why?
|
| Helicobacter felis | 1 | 2006 | 17 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2007 | 130 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 375 | 0.020 |
Why?
|
| Malpractice | 1 | 2006 | 17 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2006 | 55 | 0.020 |
Why?
|
| Stomach | 1 | 2006 | 84 | 0.020 |
Why?
|
| Critical Care | 1 | 2010 | 412 | 0.020 |
Why?
|
| Pregnancy | 2 | 2004 | 2354 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2009 | 839 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 298 | 0.020 |
Why?
|
| Cell Death | 1 | 2007 | 268 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2007 | 259 | 0.020 |
Why?
|
| Video Recording | 1 | 2006 | 126 | 0.020 |
Why?
|
| Viral Plaque Assay | 1 | 2005 | 16 | 0.020 |
Why?
|
| Intestines | 1 | 2006 | 156 | 0.020 |
Why?
|
| Magnetics | 1 | 2005 | 53 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 291 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 34 | 0.020 |
Why?
|
| Marital Status | 1 | 2005 | 43 | 0.020 |
Why?
|
| Thailand | 1 | 2005 | 94 | 0.020 |
Why?
|
| Television | 1 | 2005 | 22 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 2443 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 219 | 0.010 |
Why?
|
| New Jersey | 1 | 2004 | 26 | 0.010 |
Why?
|
| Hemodilution | 1 | 2004 | 12 | 0.010 |
Why?
|
| Pediatrics | 1 | 2007 | 266 | 0.010 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2004 | 1 | 0.010 |
Why?
|
| New York | 1 | 2004 | 137 | 0.010 |
Why?
|
| Maternal Age | 1 | 2004 | 34 | 0.010 |
Why?
|
| Liability, Legal | 1 | 2004 | 16 | 0.010 |
Why?
|
| Rehabilitation Centers | 1 | 2004 | 11 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 2004 | 22 | 0.010 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2004 | 30 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 46 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2004 | 78 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 54 | 0.010 |
Why?
|
| Hospices | 1 | 2004 | 33 | 0.010 |
Why?
|
| Educational Status | 1 | 2005 | 271 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 183 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 807 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2005 | 258 | 0.010 |
Why?
|
| Trust | 1 | 2004 | 69 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2004 | 220 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 150 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 702 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2004 | 247 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 2005 | 130 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 176 | 0.010 |
Why?
|
| Spine | 1 | 2003 | 48 | 0.010 |
Why?
|
| Physical Exertion | 1 | 2003 | 78 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2004 | 214 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2004 | 318 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 905 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 309 | 0.010 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2002 | 17 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 348 | 0.010 |
Why?
|
| Immunization | 1 | 2002 | 127 | 0.010 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2001 | 13 | 0.010 |
Why?
|
| Immunoassay | 1 | 2001 | 51 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 669 | 0.010 |
Why?
|
| Arousal | 1 | 2000 | 42 | 0.010 |
Why?
|
| Decision Making | 1 | 2002 | 391 | 0.010 |
Why?
|